Dr. Anthony S. Fiorino, also known as Tony, M.D., Ph.D., has been the Chief Medical Officer and Chief Operating Officer at Immune Pharmaceuticals, Inc. since August 14, 2017. Dr. Fiorino served as President and Chief Executive Officer of Triumvira Immunologics from 2015 to 2017. Dr. Fiorino served as the Chief Medical Advisor of BrainStorm Cell Therapeutics, Inc. from November 1, 2015 to April 30, 2016. He served as the Chief Executive Officer of BrainStorm Cell Therapeutics Inc. from June 9, 2014 to September 2015. Dr. Fiorino has 20 years of extensive experience in both biotechnology finance and drug development. Prior to this, he was a Managing Director at Greywall Asset Management LP since January 2013. Previously, Dr. Fiorino was the Founder at EnzymeRx, Inc. and served as its President and Chief Executive Officer from 2008 to 2010. He served as a Biotechnology Analyst at Citigroup Asset Management. Dr. Fiorino worked his first few years on Wall Street as an Equity Analyst at JP Morgan Chase & Co, Research Division. He served as a Vice President and Portfolio Manager at Pequot Capital Management Inc. and a Portfolio Manager at Sands Point Partners where he managed long-short biotechnology portfolios. He served as a Director of Navidea Biopharmaceuticals, Inc., since March 23, 2016 until October 9, 2017. Dr. Fiorino serves as a Director of Stemline. Prior to entering the world of finance, he trained in Medicine and Dermatology at the Hospital of the University of Pennsylvania. Dr. Fiorino was elected to Alpha Omega Alpha, Phi Beta Kappa and Sigma Xi and has authored over 20 publications in the medical and scientific literature. Dr. Fiorino earned an M.D. in 1996 and a Ph.D. in 1995 from the Albert Einstein College of Medicine where, he studied the differentiation of liver progenitor cells and a B.S. in Biology from the Massachusetts Institute of Technology in 1989.